(0.30%) 5 115.19 points
(0.30%) 38 355 points
(0.34%) 15 982 points
(-0.91%) $83.09
(5.77%) $2.03
(0.36%) $2 355.60
(0.44%) $27.66
(4.02%) $959.15
(-0.23%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $11.34
発行日: 14 2月 2024 @ 05:41
リターン: -6.17%
前回のシグナル: 2月 13 - 05:34
前回のシグナル:
リターン: -3.57 %
Live Chart Being Loaded With Signals
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation...
Stats | |
---|---|
本日の出来高 | 85 541.00 |
平均出来高 | 470 853 |
時価総額 | 376.26M |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $-0.250 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.19 |
ATR14 | $0.0210 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Opaleye Management Inc. | Buy | 20 000 | Common Stock, par value $0.001 per share |
2024-04-24 | Opaleye Management Inc. | Buy | 8 285 | Common Stock, par value $0.001 per share |
2024-04-23 | Opaleye Management Inc. | Buy | 11 715 | Common Stock, par value $0.001 per share |
2024-04-19 | Opaleye Management Inc. | Buy | 29 400 | Common Stock, par value $0.001 per share |
2024-03-28 | Opaleye Management Inc. | Buy | 50 000 | Common Stock, par value $0.001 per share |
INSIDER POWER |
---|
13.46 |
Last 96 transactions |
Buy: 4 652 789 | Sell: 3 289 598 |
ボリューム 相関
Harrow Health Inc 相関
10 最も正の相関 | |
---|---|
SY | 0.94 |
BRIVU | 0.939 |
ARTEU | 0.939 |
ALSA | 0.936 |
PPYAU | 0.935 |
IOAC | 0.935 |
LCAA | 0.934 |
GPACU | 0.934 |
ATEC | 0.933 |
ALTR | 0.933 |
10 最も負の相関 | |
---|---|
CSSEP | -0.947 |
GOOD | -0.946 |
NAKD | -0.933 |
JAGX | -0.932 |
PCSA | -0.931 |
SIDU | -0.93 |
VFF | -0.929 |
NARI | -0.925 |
ALXO | -0.924 |
XPDI | -0.924 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Harrow Health Inc 相関 - 通貨/商品
Harrow Health Inc 財務諸表
Annual | 2023 |
収益: | $130.19M |
総利益: | $90.55M (69.55 %) |
EPS: | $-0.750 |
FY | 2023 |
収益: | $130.19M |
総利益: | $90.55M (69.55 %) |
EPS: | $-0.750 |
FY | 2022 |
収益: | $88.60M |
総利益: | $63.21M (71.35 %) |
EPS: | $-0.510 |
FY | 2021 |
収益: | $72.48M |
総利益: | $54.26M (74.87 %) |
EPS: | $-0.690 |
Financial Reports:
No articles found.
Harrow Health Inc
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。